Home > Boards > US Listed > Biotechs >

Bristol Myers Squibb (BMY)

BMY RSS Feed
Add BMY Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 4/30/2021 9:25:59 AM - Followers: 42 - Board type: Free - Posts Today: 0
BMY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMY News: DarwinHealth annonce une collaboration de recherche avec Bristol Myers Squibb en vue du lancement d'une initiative novatrice ... 07:12 PM
BMY News: Current Report Filing (8-k) 04:57 PM
BMY News: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiati... 08:14 AM
BMY News: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiati... 08:03 AM
BMY News: DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiati... 08:03 AM
News News Alert: DarwinHealth annonce une collaboration de recherche avec Bristol Myers Squibb en vue du lancement d'une initiative novatrice ... 05/06/2021 07:12:00 PM
PostSubject
#1000  Sticky Note BMY 1Q21 results—2021_non-GAAP_EPS_guidance_unchanged—($7.35-7.55): DewDiligence 04/29/21 08:10:48 AM
#1005   PDUFA for Opdivo in adjuvant MUIC is 9/3/21 DewDiligence 04/30/21 09:25:59 AM
#1004   62.58 - close enough JohnLocke101 04/29/21 01:49:41 PM
#1003   Bit on some Jan 2022 call options @ 62.50 JohnLocke101 04/29/21 12:39:43 PM
#1002   Order in @ $62.50 JohnLocke101 04/29/21 12:24:09 PM
#1001   BMY 1Q21 CC slides: DewDiligence 04/29/21 09:00:40 AM
#1000   BMY 1Q21 results—2021_non-GAAP_EPS_guidance_unchanged—($7.35-7.55): DewDiligence 04/29/21 08:10:48 AM
#999   Deucravacitinib phase-3 data update in psoriasis—(in conjunction with DewDiligence 04/23/21 10:50:17 AM
#998   BMY AAD slide set: DewDiligence 04/23/21 10:23:30 AM
#997   FDA approves Opdivo/chemo for first-line gastric cancer—irrespective of DewDiligence 04/16/21 04:32:47 PM
#996   BMY reports (stellar) results of CHECKMATE-816 in neoadjuvant NSCLC: DewDiligence 04/10/21 02:27:16 PM
#995   Opdivo/Yervoy and Opdivo/chemo–>statsig-superior_OS_vs_chemo_alone_in_esophageal DewDiligence 04/08/21 09:04:16 AM
#994   BMY/BLUE—FDA_approves Abecma—(f/k/a_bb2121/ide-cel)—BCMA_CAR-T_for_MM: DewDiligence 03/27/21 12:35:47 PM
#993   BMY’s Relatlimab_(anti-LAG-3)—>statsig_PFS_as_addend_to_Opdivo_in_1L-melanoma: DewDiligence 03/25/21 10:40:25 AM
#992   BMY PDUFA date for Mavacamten is 1/28/22: DewDiligence 03/19/21 08:37:49 AM
#991   AACR https://www.abstractsonline.com/pp8/#!/9325/presentation/2645 jondoeuk 03/10/21 07:12:35 PM
#990   BMY, MTEM ink drug-development deal: DewDiligence 02/11/21 12:33:50 PM
#989   Opdivo monotherapy shows statsig-superior DFS to placebo in DewDiligence 02/08/21 08:06:46 PM
#988   BMY’s own PR on FDA approval of Breyanzi: DewDiligence 02/05/21 07:43:25 PM
#987   FDA approves BMY’s Breyanzi (liso-cel) for B-cell lymphomas: DewDiligence 02/05/21 03:11:42 PM
#986   BMY 4Q20 CC slides: DewDiligence 02/04/21 10:02:42 AM
#985   BMY_4Q20_results—2021_non-GAAP_EPS_guidance=$7.35-7.55—(up from prior range of $ DewDiligence 02/04/21 08:11:17 AM
#984   BMY licenses COVID-19 antibody from Rockefeller University: DewDiligence 02/03/21 08:42:36 AM
#983   Deucravacitinib scores second phase-3 win in psoriasis: DewDiligence 02/02/21 09:24:05 AM
#982   Zeposia sNDA for UC has PDUFA date of DewDiligence 02/01/21 08:10:30 AM
#981   Keytruda/Yervoy_bombs_in_1L-NSCLC—numerically_worse_than_Keytruda_monotherapy: DewDiligence 01/30/21 11:52:16 AM
#980   FDA approves Opdivo/Cabometyx in 1L-RCC: DewDiligence 01/22/21 01:58:29 PM
#979   Two new PDUFA dates for Opdivo… DewDiligence 01/20/21 09:51:49 AM
#978   BMY raises buyback authorization to $6.4B (from prior DewDiligence 01/11/21 09:34:50 AM
#977   BMY slide set for JPM: DewDiligence 01/11/21 09:30:17 AM
#976   Celgene CVR goes poof: #msg-160628371. DewDiligence 01/01/21 11:33:36 AM
#975   CHECKMATE-548 study of Opdivo in glioblastoma missed primary endpoint: DewDiligence 12/23/20 09:11:42 AM
#973   CHMP approves Inrebic (fedratinib) for second-line myelofibrosis: DewDiligence 12/11/20 09:23:24 AM
#972   BMY settles US Revlimid patent with Cipla: DewDiligence 12/11/20 09:02:35 AM
#971   BMY increases annualized dividend to $1.96 (from $1.80): DewDiligence 12/10/20 08:21:05 PM
#970   BMY presents latest liso-cel data at ASH: DewDiligence 12/07/20 10:09:52 AM
#969   BMY’s ASH lineup: DewDiligence 12/05/20 10:39:16 AM
#968   FDA_unable_to_meet_BMY’s_liso-cell_PDUFA_date—(today)—due_to_COVID: https://f DewDiligence 11/16/20 05:35:22 PM
#967   BMY sells $7B of 3-30yr notes—to fund MYOK acquisition: DewDiligence 11/10/20 09:08:21 AM
#966   Keytruda+Yervoy_not_better_than_Keytruda_monotherapy_in_1L-NSCLC with PD-L1>=50% DewDiligence 11/09/20 06:46:36 PM
#965   Phase-2 Deucravacitinib data in PA: DewDiligence 11/09/20 08:48:33 AM
#964   Pulling out all the right stops as it Seeker213 11/06/20 05:21:32 AM
#963   BMY 3Q20 CC slides: DewDiligence 11/05/20 08:35:02 AM
#962   BMY 3Q20 results—raises_2020_EPS guidance: DewDiligence 11/05/20 08:11:59 AM
#961   BMY’s Deucravacitinib bests AMGN’s Otezla_in_phase-3_psoriasis_study: DewDiligence 11/03/20 08:54:33 AM
#960   https://www.businesswire.com/news/home/20201028005276/en/insitro-Announces-Five- DewDiligence 10/28/20 07:09:10 AM
#959   Opdivo/Cabometyx BLA/NDA for RCC combination therapy has 2/21/21 DewDiligence 10/19/20 10:03:16 AM
#958   Just In: $BMY Why I Think Bristol Myers whytestocks 10/17/20 08:00:30 AM
#957   BMY reports full dataset for Zeposia phase-3 in UC: DewDiligence 10/12/20 10:52:37 AM
#956   BMY’s enterprise value increased by ~$6B today, which DewDiligence 10/07/20 07:35:59 PM
#955   Opdivo/chemo shows statsig-superior pCR compared to chemo alone DewDiligence 10/07/20 02:17:37 PM
PostSubject
Consent Preferences